|
|
Article: ALTACE(R) (Ramipril) Receives New Indication to Reduce Risk of Stroke, Heart Attack and Death From Cardiovascular Causes.
- Article from:
- PR Newswire
- Article date:
- October 5, 2000
CopyrightCOPYRIGHT 2000 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Expanded Indication Brings Promise for the Millions of
Americans 55 and Over With a History of Cardiovascular Disease
MADISON, N.J., Oct. 5 /PRNewswire/ --
American Home Products Corporation (NYSE: AHP) announced today that ALTACE(R) (ramipril) received approval from the U.S. Food and Drug Administration (FDA) to reduce the risk of stroke, myocardial infarction (heart attack) and death from cardiovascular causes in patients 55 and over either with a history of coronary artery disease, stroke, or peripheral vascular disease or with diabetes and one other cardiovascular risk factor (e.g., elevated cholesterol levels, cigarette smoking, etc.). ...